InnoCare Pharma Limited (9969.HK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jisong Cui Ph.D. | Co-Founder, Chairwoman & CEO | 9.09M | -- | 1963 |
| Dr. Renbin Zhao Ph.D. | VP of Clinical Development & Medical Research and Executive Director | 3.6M | -- | 1969 |
| Mr. Xin Fu | Chief Financial Officer | -- | -- | 1978 |
| Mr. Nan Gao | Chief Operating Officer | -- | -- | 1974 |
| Yue Tan | Accounting Supervisor | -- | -- | -- |
| Dr. Xiangyang Chen Ph.D. | Chief Technology Officer | -- | -- | 1967 |
| Ms. Junsu Wang | General Counsel | -- | -- | 1977 |
| Mr. Davy Ouyang Ph.D. | VP & Head of Biology | -- | -- | -- |
| Mr. Jeff Chen | Chief Commercial Officer | -- | -- | -- |
| Bei Yuan | Secretary of the Board | -- | -- | -- |
InnoCare Pharma Limited
- Sector:
- Healthcare
- Industry: Biotechnology
Description
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, the company develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, the company offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. The company has a clinical collaboration with ArriVent Biopharma, Inc. to evaluate the anti-tumor activity and safety of ICP-189 combined with furmonertinib in patients with advanced non-small cell lung cancer. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Corporate Governance
Upcoming Events
March 27, 2025 at 11:27 AM UTC
InnoCare Pharma Limited Earnings Date
Recent Events
Recent Events Information Not Available